RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

J. Niederst, Matthew; V. Sequist, Lecia; T. Poirier, John; H. Mermel, Craig; L. Lockerman, Elizabeth; R. Garcia, Angel; Katayama, Ryohei; Costa, Carlotta; N. Ross, Kenneth; Morán, Teresa; Howe, Emily; Fulton, Linnea; E. Mulvey, Hillary; A. Bernardo, Lindsay; Mohamoud, Farhiya; Miyoshi, Norikatsu; A. VanderLaan, Paul; B. Costa, Daniel; A. Jänne, Pasi; R. Borger, Darrell; Ramaswamy, Sridhar; Shioda, Toshi; John Iafrate, A.; Getz, Gad; M. Rudin, Charles; Mino–Kenudson, Mari; A. Engelman, Jeffrey

doi:10.1038/ncomms7377

Public

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Published in Nature Communications • Mar 11, 2015

Authors:

Matthew J. Niederst

Lecia V. Sequist

John T. Poirier

Abstract

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cel...

Subject

Epidermal growth factor receptor

Cancer research

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!